Aspen moves to reassure investors after share price fall

Cape Town - The share price of JSE-listed Aspen Pharmacare Holdings [JSE:APN] appears to have recovered after a rocky start on Tuesday, caused by rumours that research group Viceroy was investigating the pharmaceutical company.

Aspen's share price opened at R261.01 a share on Tuesday, and reached an intraday low of R234.98 at 13:00 before it started to recover. 

By 16:40 it was trading at R250.81, down 4.3% on the day.  

In an afternoon notice to shareholders, the pharmaceutical company said it was aware of speculation that it was being investigated by Viceroy.

“Aspen shareholders are advised that it has had no contact with Viceroy Research and, as such, is unable to confirm that this speculation is correct,” it said. 

Viceroy research had released an exposé on Stellenbosch-headquartered global retailer Steinhoff in December. It did not immediately reply to a Fin24 request for comment. 

Aspen also indicated that it was not aware of “price sensitive” information that required communication to shareholders.

“Trading in the current financial year has been consistent with the prospects communicated to shareholders in the 2017 financial year results announcement as published on SENS on 14 September 2017,” the notice read.

Earlier, the deputy chair of Sasfin Securities David Shapiro had tweeted that investors were "perplexed" by the share's fall. 

Shapiro told Fin24 by phone on Tuesday afternoon that a drop in the share price without any reasonable information was worrying, especially as the pace of the fall appeared to be “aggressive”.

“We see a sell-off and we can’t make head or tail of it,” he said.

There was similarly a sell-off from halfway through November, which saw the share price come down from over R300 to approach R240, he noted. Essentially the share price has fallen to levels it was two years ago, he explained.

He also indicated that investors were sensitive in light of the fallout from Steinhoff.

Last year Aspen faced probes by the Competition Commission over the excessive pricing of cancer medication. The investigation was dropped. Shapiro said that these probes were not enough to warrant the loss in share value as has been observed. 

* Sign up to Fin24's top news in your inbox: SUBSCRIBE TO FIN24 NEWSLETTER

ZAR/USD
17.02
(-0.49)
ZAR/GBP
21.24
(-0.35)
ZAR/EUR
19.16
(-0.40)
ZAR/AUD
11.83
(-0.68)
ZAR/JPY
0.16
(-0.31)
Gold
1775.00
(+0.00)
Silver
18.02
(+0.64)
Platinum
807.67
(+0.22)
Brent Crude
42.92
(+2.64)
Palladium
1919.00
(+1.71)
All Share
54521.90
(-0.17)
Top 40
50179.89
(-0.26)
Financial 15
10150.02
(-0.64)
Industrial 25
76554.73
(+0.52)
Resource 10
50138.02
(-1.24)
All JSE data delayed by at least 15 minutes morningstar logo
Company Snapshot
Voting Booth
Please select an option Oops! Something went wrong, please try again later.
Results
I'm not really directly affected
18% - 1571 votes
I am taking a hit, but should be able to recover in the next year
23% - 2064 votes
My finances have been devastated
34% - 3077 votes
It's still too early to know what the full effect will be
25% - 2234 votes
Vote